Photo of Sara I. Pai,  MD, PhD

Sara I. Pai, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital


sara.pai@mgh.harvard.edu

Sara I. Pai, MD, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Surgery, Harvard Medical School
  • Associate Surgeon, Surgery, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Sara Pai is an Associate Professor at Harvard Medical School and the Massachusetts General Hospital. She graduated Summa Cum Laude from Dartmouth College with a major in Biochemistry and Molecular Biology. After graduating Dartmouth, she completed the MD/PhD program at Johns Hopkins University School of Medicine in which she obtained her PhD training in cancer immunology and vaccines. After completing her residency in Otolaryngology-Head and Neck Surgery at Johns Hopkins Hospital, she joined its faculty in 2007 where she led a therapeutic HPV vaccine clinical trial which was supported by the Head and Neck Cancer SPORE grant. In 2014, she joined the faculty in the Department of Surgery at the Massachusetts General Hospital. Her research interests focus on better understanding how human papillomavirus (HPV) can evade the immune system and strategies that can be applied to reactivate the host immune response against the virus through vaccines and immune modulatory drugs. She leads several HPV related investigator-initiated clinical immunotherapy trials and has a research laboratory that is supported by the National Institutes of Health (NIH) as well as industry. She serves on grant and strategic review panels at the NIH and international government sponsored programs in the UK, Hong Kong, and Portugal. She is on the editorial board of lead scientific journals as well as serves on the advisory boards for several pharmaceutical companies.

Publications

Powered by Harvard Catalyst
  • Pai SI, Faquin WC, Sadow PM, Pittet MJ, Weissleder R. New technology on the horizon: Fast analytical screening technique FNA (FAST-FNA) enables rapid, multiplex biomarker analysis in head and neck cancers. Cancer Cytopathol 2020. PubMed
  • Mahmood U, Bang A, Chen YH, Mak RH, Lorch JH, Hanna GJ, Nishino M, Manuszak C, Thrash EM, Severgnini M, Sanborn M, Sridharan V, Margalit DN, Tishler RB, Busse PM, Willers H, Mamon HJ, Yoo HJ, Pai SI, Wirth LJ, Haddad RI, Chau NG, Schoenfeld JD. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys 2020. PubMed
  • Wolkow N, Jakobiec FA, Afrogheh AH, Pai SI, Faquin WC. High Expression of PD-L1 and PD-L2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors. Am J Ophthalmol 2020. PubMed
  • Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol 2020. PubMed
  • Wolkow N, Jakobiec FA, Afrogheh AH, Kidd M, Eagle RC, Pai SI, Faquin WC. PD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications. Ophthal Plast Reconstr Surg 2020. PubMed
  • Banik G, Betts CB, Liudahl SM, Sivagnanam S, Kawashima R, Cotechini T, Larson W, Goecks J, Pai SI, Clayburgh DR, Tsujikawa T, Coussens LM. High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. Methods Enzymol 2020; 635:1-20. PubMed
  • Gastman B, Agarwal PK, Berger A, Boland G, Broderick S, Butterfield LH, Byrd D, Fecci PE, Ferris RL, Fong Y, Goff SL, Grabowski MM, Ito F, Lim M, Lotze MT, Mahdi H, Malafa M, Morris CD, Murthy P, Neves RI, Odunsi A, Pai SI, Prabhakaran S, Rosenberg SA, Saoud R, Sethuraman J, Skitzki J, Slingluff CL, Sondak VK, Sunwoo JB, Turcotte S, Yeung CC, Kaufman HL. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer 2021. PubMed
  • Pai SI, Cesano A, Marincola FM. The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier. Cancer Treat Res 2020; 180:173-195. PubMed
  • Pai S, Blaisdell D, Brodie R, Carlson R, Finnes H, Galioto M, Jensen RE, Valuck T, Sepulveda AR, Kaufman HL. Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit. J Immunother Cancer 2020. PubMed
  • Pai SI, Marincola FM. Peripheral Circulating CD45RAFOXP3 T Regulatory (T) II Cells Provide a Window into the Activity of Intratumoral T Cells. Trends Cancer 2020; 6:3-6. PubMed
  • Pai SI, Cohen EEW, Lin D, Fountzilas G, Kim ES, Mehlhorn H, Baste N, Clayburgh D, Lipworth L, Resteghini C, Shara N, Fujii T, Zhang J, Stokes M, Wang H, Twumasi-Ankrah P, Wildsmith S, Khaliq A, Melillo G, Shire N. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Transl Med 2019; 17:429. PubMed
  • Ishida E, Lee J, Campbell JS, Chakravarty PD, Katori Y, Ogawa T, Johnson L, Mukhopadhyay A, Faquin WC, Lin DT, Wirth LJ, Pierce RH, Pai SI. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model. Cancer Immunol Immunother 2019. PubMed
  • Pai SI, Faivre S, Licitra L, Machiels JP, Vermorken JB, Bruzzi P, Gruenwald V, Giglio RE, Leemans CR, Seiwert TY, Soulieres D. Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040). J Immunother Cancer 2019; 7:96. PubMed
  • Wolkow N, Jakobiec FA, Afrogheh AH, Eagle RC, Pai SI, Faquin WC. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications. Am J Ophthalmol 2019; 200:226-241. PubMed
  • Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. Immunity 2018; 49:1148-1161.e7. PubMed
  • Rosenbaum MW, Gigliotti BJ, Pai SI, Parangi S, Wachtel H, Mino-Kenudson M, Gunda V, Faquin WC. PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. Endocr Pathol 2018; 29:59-67. PubMed
  • Pai SI, Jack Lee J, Carey TE, Westra WH, Ferrone S, Moore C, Mosunjac MB, Shin DM, Ferris RL, . HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol 2018; 77:92-97. PubMed
  • Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, Snyder-Cappione JE, Belkina AC, Bais MV, Monti S, Kukuruzinska MA. Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer. Genome Med 2018; 10:54. PubMed
  • Pai SI, Wirth LJ. Checkpoint cluster: biomarkers of response. Emerg Top Life Sci 2021; 1:501-508. PubMed
  • Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR, . Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 2017. PubMed
  • Mattox A, Lee J, Westra WH, Pierce RH, Ghossein R, Faquin WC, Diefenbach TJ, Morris LG, Lin DT, Wirth LJ, Lefranc-Torres A, Ishida E, Chakravarty PD, Johnson L, Zeng Y, Chen H, Poznansky MC, Iyengar NM, Pai SI. PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4+ TILs in the presence of PD-L1+ TAMs. Cancer Res 2017. PubMed
  • Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J, Pai SI, Sidransky D, Westra WH, William WN, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM, . Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head Neck 2017. PubMed
  • Pai SI, Faquin WC. Programmed cell death ligand 1 as a biomarker in head and neck cancer. Cancer 2017; 125:529-533. PubMed
  • Mohan S, Pai SI, Bhattacharyya N. Adjuvant radiotherapy is not supported in patients with verrucous carcinoma of the oral cavity. Laryngoscope 2017; 127:1334-1338. PubMed
  • Osho AA, Azzoli CJ, Pai S, Mino-Kenudson M, Faquin WC, Huynh TG, Lanuti M, Mathisen DJ, Muniappan A. Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy. Ann Thorac Surg 2017; 103:e123-e125. PubMed
  • Walline HM, Carey TE, Goudsmit CM, Bellile EL, D'Souza G, Peterson LA, McHugh JB, Pai SI, Lee JJ, Shin DM, Ferris RL, . High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 2016; 15:179-188. PubMed
  • Pai SI, Zandberg DP, Strome SE. The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. Oral Oncol 2016; 61:152-8. PubMed
  • Brotherton JM, Jit M, Gravitt PE, Brisson M, Kreimer AR, Pai SI, Fakhry C, Monsonego J, Franceschi S. Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. Int. J. Cancer 2016; 139:510-7. PubMed
  • Peng S, Mattox A, Best SR, Barbu AM, Burns JA, Akpeng B, Jeang J, Yang B, Ishida E, Hung CF, Wu TC, Pai SI. Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes. Cancer Immunol Immunother 2016; 65:261-71. PubMed
  • Anderson KS, Gerber JE, D'Souza G, Pai SI, Cheng JN, Alam R, Kesiraju S, Chowell D, Gross ND, Haddad R, Gillison ML, Posner M. Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncol 2015; 51:751-8. PubMed
  • Ahn J, Bishop JA, Akpeng B, Pai SI, Best SR. Xenograft model for therapeutic drug testing in recurrent respiratory papillomatosis. Ann. Otol. Rhinol. Laryngol. 2015; 124:110-5. PubMed
  • Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE. In-situ tumor vaccination: Bringing the fight to the tumor. Hum Vaccin Immunother 2015; 11:1901-9. PubMed
  • Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD, Pai SI, Hung CF, Wu TC, Roden RB. Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS ONE 2015; 10:e116389. PubMed
Hide